Last reviewed · How we verify
Single-entity oral triptans — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Single-entity oral triptans (Single-entity oral triptans) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Single-entity oral triptans TARGET | Single-entity oral triptans | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Single-entity oral triptans CI watch — RSS
- Single-entity oral triptans CI watch — Atom
- Single-entity oral triptans CI watch — JSON
- Single-entity oral triptans alone — RSS
Cite this brief
Drug Landscape (2026). Single-entity oral triptans — Competitive Intelligence Brief. https://druglandscape.com/ci/single-entity-oral-triptans. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab